New drug duo aims to wipe out leukemia cells in First-Line treatment
NCT ID NCT07557056
First seen May 08, 2026 · Last updated May 08, 2026
Summary
This study tests a combination of two oral drugs, nemtabrutinib and venetoclax, as the first treatment for people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). The goal is to see if the combo can eliminate cancer cells deep enough that they become undetectable by sensitive testing. About 25 adults who have not had prior treatment for their CLL/SLL will take both pills for 14 cycles. The main focus is on safety and how well the drugs work together.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC LYMPHOCYTIC LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Ohio State University Comprehensive Cancer Center
Columbus, Ohio, 43210, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.